Allogene Therapeutics
Peng Cui has a strong background in the pharmaceutical industry, with experience in various roles and companies. Cui most recently worked at Allogene Therapeutics as the Associate Director and Head of QC Chemistry/Biochemistry Lab and Raw Material Management. Prior to that, Cui spent several years at Regeneron Pharmaceuticals, Inc. as a Senior Manager in Quality Control. Cui also worked at AMRI as a Senior Research Scientist and at UCLA as a Research Associate.
Peng Cui holds a Ph.D. degree in Organic/Medicinal Chemistry from the University of Virginia. Prior to that, they completed their Bachelor of Science degree in Chemistry at Peking University.
This person is not in the org chart
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.